Posted by Michael Wonder on 14 Mar 2017
Novartis wins U.S. approval for breast cancer drug; to compete with Pfizer's Ibrance
14 March 2017 - Kisqali priced 18-20% cheaper than Pfizer's Ibrance.
Novartis has won U.S. FDA approval for Kisqali to treat post-menopausal women who have a difficult-to-treat form of breast cancer, challenging U.S. rival Pfizer's Ibrance.
The Swiss company has priced Kisqali to be cheaper than Ibrance, which analysts said could help it win business, though Kisqali's approval includes additional patient monitoring requirements that could work against the new drug.
Novartis considers Kisqali to be one of its stable of 13 new medicines with blockbuster potential for annual revenue in the billions of dollars. Analysts see global annual sales reaching $1.5 billion by 2022, Thomson Reuters data shows.
